Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5196514
Max Phase: Preclinical
Molecular Formula: C46H56FN7O9S
Molecular Weight: 902.06
Associated Items:
ID: ALA5196514
Max Phase: Preclinical
Molecular Formula: C46H56FN7O9S
Molecular Weight: 902.06
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)c2c(C)[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c2C)C(C)(C)C)cc1
Standard InChI: InChI=1S/C46H56FN7O9S/c1-26-36(21-34-33-19-31(47)11-12-35(33)52-42(34)57)51-27(2)39(26)44(59)48-13-14-61-15-16-62-17-18-63-24-38(56)53-41(46(4,5)6)45(60)54-23-32(55)20-37(54)43(58)49-22-29-7-9-30(10-8-29)40-28(3)50-25-64-40/h7-12,19,21,25,32,37,41,51,55H,13-18,20,22-24H2,1-6H3,(H,48,59)(H,49,58)(H,52,57)(H,53,56)/b34-21-/t32-,37+,41-/m1/s1
Standard InChI Key: GTDUQLRYMOBIGB-NXWMYEPUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 902.06 | Molecular Weight (Monoisotopic): 901.3844 | AlogP: 4.28 | #Rotatable Bonds: 19 |
Polar Surface Area: 213.31 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 2.65 | CX LogP: 2.42 | CX LogD: 2.42 |
Aromatic Rings: 4 | Heavy Atoms: 64 | QED Weighted: 0.06 | Np Likeness Score: -0.78 |
1. Zhai J, Li C, Sun B, Wang S, Cui Y, Gao Q, Sang F.. (2022) Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines., 78 [PMID:36332882] [10.1016/j.bmcl.2022.129041] |
Source(1):